Other studies of CREBBP/EP300 inhibition show similarly modest changes in chromatin accessibility in both multiple myeloma [34] and embryonic stem cells [8], but this phenomenon has not been observed in hormone-dependent cancers. The gene discussed is CREBBP; the disease is plasma cell myeloma.